Abstract 5499: Efficacy of icotinib as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE)

医学 内科学 腺癌 临床终点 肿瘤科 表皮生长因子受体 辅助治疗 肺癌 非小细胞肺癌 佐剂 胃肠病学 癌症 临床试验 A549电池
作者
Kun Qian,Bin Hu,Ming He,Zitong Wang,Yu Liu,Huagang Liang,Zhiyong Su,Y Y Cui,Lijun Liu,Yi Zhang
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (12_Supplement): 5499-5499
标识
DOI:10.1158/1538-7445.am2022-5499
摘要

Abstract Background: Currently, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have been proved to significantly improve the clinical outcome of patients with EGFR-mutant non-small-cell lung cancer (NSCLC). Icotinib is an oral, reversible and selective first-generation EGFR-TKI. The survival benefits of 1-year and 2-year adjuvant icotinib in patients with EGFR-mutant NSCLC have been confirmed in previous studies. However, the optimal duration of adjuvant icotinib remains unknown. This study (ICAPE) evaluated the efficacy of 1.5-year adjuvant therapy with icotinib for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma. Methods: Patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma were enrolled in the multicenter, open-label, single-arm, phase II study. Eligible patients received oral icotinib 125 mg thrice daily for 1.5 years after complete surgical resection. Primary endpoint was disease-free survival (DFS). Secondary endpoints included 1-year, 3-year, as well as 5-year OS rates, and the DFS according to the BIM mutation status (mutant-type and wild-type) and EGFR mutation types (19 del and 21 L858R). Results: Between March 2014 and January 2018, 79 patients were enrolled. The median follow-up time was 39.7 months with a median DFS and overall survival (OS) of 41.4 months (95% CI: 33.6-51.8) and 67.0 months (95% CI: 21.2-not reached [NR]), respectively. The 1-year, 3-year and 5-year OS rates were 100%, 83.3%, and 61.7%, respectively. No significant difference was found in the median DFS between patients with Bcl-2 interacting mediator of cell death (BIM) mutant-type and wild-type (NR vs. 41.7 months; p=0.75) and no significant difference was found in the median DFS according to EGFR mutation types (all p>0.05). Conclusions: The phase II ICAPE study demonstrated that 1.5-year adjuvant therapy with icotinib had a favorable survival benefit in patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma with a long median DFS and high 5-year OS rates which is consistent with other icotinib’s study. Icotinib is suggested to be used as an adjuvant therapy option in IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma. Citation Format: Kun Qian, Bin Hu, Ming He, Zi-Tong Wang, Yu Liu, Hua-Gang Liang, Zhi-Yong Su, Yu-Shang Cui, Li-Jun Liu, Yi Zhang. Efficacy of icotinib as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5499.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
jiaokaige完成签到,获得积分10
刚刚
lemon完成签到,获得积分10
刚刚
1234完成签到,获得积分10
刚刚
Li完成签到,获得积分10
1秒前
follower8107发布了新的文献求助10
1秒前
1秒前
团子呀完成签到 ,获得积分10
1秒前
ubless607的应助被xiao采纳,获得10
2秒前
云府有知发布了新的文献求助10
2秒前
YUEYUEHENCHEN发布了新的文献求助10
2秒前
2秒前
Weslie完成签到 ,获得积分10
2秒前
2秒前
香蕉觅云的应助被碧蓝的若风采纳,获得10
2秒前
HHH完成签到,获得积分10
2秒前
3秒前
lemon完成签到,获得积分10
3秒前
3秒前
ling完成签到,获得积分10
3秒前
xiaoyan完成签到,获得积分10
4秒前
yyf完成签到 ,获得积分10
4秒前
HO发布了新的文献求助10
4秒前
5秒前
Orange的应助被小李采纳,获得10
5秒前
5秒前
蒸蒸日上完成签到,获得积分10
5秒前
LordRowan完成签到,获得积分10
5秒前
CC完成签到,获得积分10
5秒前
5秒前
兴奋平露完成签到,获得积分10
5秒前
鸭蛋完成签到,获得积分10
6秒前
6秒前
啊管今天吃什么完成签到,获得积分10
6秒前
乐空思完成签到,获得积分0
6秒前
陈_Ccc完成签到 ,获得积分10
7秒前
syc完成签到,获得积分10
7秒前
zxf完成签到,获得积分10
7秒前
lk完成签到,获得积分10
7秒前
大模型的应助被XX采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8174058
求助须知:如何正确求助?哪些是违规求助? 9566129
关于积分的说明 21784894
捐赠科研通 7768250
什么是DOI,文献DOI怎么找? 3431686
关于科研通互助平台的介绍 2555907
邀请新用户注册赠送积分活动 2476936